Symposia: CAR-T Cell Therapies: Basic and Translational
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Adult, Lymphoid Leukemias, ALL, Hodgkin lymphoma, Translational Research, Non-Hodgkin lymphoma, Lymphomas, CLL, Drug development, Elderly, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, LGL, Genomics, Diversity, Equity, and Inclusion (DEI), T Cell lymphoma, Hematopoiesis, Pediatric, Diseases, Immune mechanism, Indolent lymphoma, Treatment Considerations, Biological therapies, Immunology, Aggressive lymphoma, Immunotherapy, Lymphoid Malignancies, Metabolism, Young adult , Biological Processes, Monoclonal Antibody Therapy, Molecular biology, Study Population, Human
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Adult, Lymphoid Leukemias, ALL, Hodgkin lymphoma, Translational Research, Non-Hodgkin lymphoma, Lymphomas, CLL, Drug development, Elderly, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, LGL, Genomics, Diversity, Equity, and Inclusion (DEI), T Cell lymphoma, Hematopoiesis, Pediatric, Diseases, Immune mechanism, Indolent lymphoma, Treatment Considerations, Biological therapies, Immunology, Aggressive lymphoma, Immunotherapy, Lymphoid Malignancies, Metabolism, Young adult , Biological Processes, Monoclonal Antibody Therapy, Molecular biology, Study Population, Human
Monday, December 9, 2024: 4:30 PM-6:00 PM
Room 6CF
(San Diego Convention Center)
Moderators:
Franziska Blaeschke, MD, PhD, German Cancer Research Center
and
Sarah Tettamanti, PhD, Fondazione IRCCS San Gerardo dei Tintori
Disclosures:
No relevant conflicts of interest to declare.
This session will highlight new CAR T cell targets and innovative strategies to augment CAR T cell response.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH